1.A biomimetic nanoplatform for customized photothermal therapy of HNSCC evaluated on patient-derived xenograft models.
Qi WU ; Lan CHEN ; Xiaojuan HUANG ; Jiayi LIN ; Jiamin GAO ; Guizhu YANG ; Yaping WU ; Chong WANG ; Xindan KANG ; Yanli YAO ; Yujue WANG ; Mengzhu XUE ; Xin LUAN ; Xin CHEN ; Zhiyuan ZHANG ; Shuyang SUN
International Journal of Oral Science 2023;15(1):9-9
Cancer cell membrane (CCM) derived nanotechnology functionalizes nanoparticles (NPs) to recognize homologous cells, exhibiting translational potential in accurate tumor therapy. However, these nanoplatforms are majorly generated from fixed cell lines and are typically evaluated in cell line-derived subcutaneous-xenografts (CDX), ignoring the tumor heterogeneity and differentiation from inter- and intra- individuals and microenvironments between heterotopic- and orthotopic-tumors, limiting the therapeutic efficiency of such nanoplatforms. Herein, various biomimetic nanoplatforms (CCM-modified gold@Carbon, i.e., Au@C-CCM) were fabricated by coating CCMs of head and neck squamous cell carcinoma (HNSCC) cell lines and patient-derived cells on the surface of Au@C NP. The generated Au@C-CCMs were evaluated on corresponding CDX, tongue orthotopic xenograft (TOX), immune-competent primary and distant tumor models, and patient-derived xenograft (PDX) models. The Au@C-CCM generates a photothermal conversion efficiency up to 44.2% for primary HNSCC therapy and induced immunotherapy to inhibit metastasis via photothermal therapy-induced immunogenic cell death. The homologous CCM endowed the nanoplatforms with optimal targeting properties for the highest therapeutic efficiency, far above those with mismatched CCMs, resulting in distinct tumor ablation and tumor growth inhibition in all four models. This work reinforces the feasibility of biomimetic NPs combining modular designed CMs and functional cores for customized treatment of HNSCC, can be further extended to other malignant tumors therapy.
Animals
;
Humans
;
Squamous Cell Carcinoma of Head and Neck/therapy*
;
Heterografts
;
Photothermal Therapy
;
Biomimetics
;
Disease Models, Animal
;
Head and Neck Neoplasms/therapy*
;
Cell Line, Tumor
;
Tumor Microenvironment
2.Correction To: A biomimetic nanoplatform for customized photothermal therapy of HNSCC evaluated on patient-derived xenograft models.
Qi WU ; Lan CHEN ; Xiaojuan HUANG ; Jiayi LIN ; Jiamin GAO ; Guizhu YANG ; Yaping WU ; Chong WANG ; Xindan KANG ; Yanli YAO ; Yujue WANG ; Mengzhu XUE ; Xin LUAN ; Xin CHEN ; Zhiyuan ZHANG ; Shuyang SUN
International Journal of Oral Science 2023;15(1):12-12
3.Epigallocatechin gallate induces gene demethylation to promote acute myeloid leukemia cell apoptosis by regulating p19-p53-p21 signaling pathway.
Mingcai WU ; Ming JIANG ; Mengya XUE ; Qing LI ; Bing CHENG ; Mengzhu HUANG ; Lei XU ; Yao ZHANG
Journal of Southern Medical University 2020;40(9):1230-1238
OBJECTIVE:
To investigate the mechanism by which epigallocatechin gallate (EGCG) induces gene demethylation and promotes the apoptosis of acute myeloid leukemia KG-1 and THP-1 cell lines.
METHODS:
KG-1 and THP-1 cells treated with 25, 50, 75, 100 or 150 μg/mL EGCG for 48 h were examined for gene methylation using MSP and for cell proliferation using MTT assay. The changes in cell cycle and apoptosis of the two cell lines after treatment with EGCG for 48 h were detected using flow cytometry. The mRNA and protein expressions of DNMT1, CHD5, p19, p53 and p21 in the cells were detected using RT-quantitative PCR and Western blot.
RESULTS:
EGCG dose-dependently reversed hypermethylation of gene and reduced the cell viability in both KG-1 and THP-1 cells ( < 0.05). EGCG treatment caused obvious cell cycle arrest in G1 phase, significantly increased cell apoptosis, downregulated the expression of DNMT1 and upregulated the expressions of CHD5, p19, p53 and p21 in KG-1 and THP-1 cells ( < 0.05).
CONCLUSIONS
EGCG reduces hypermethylation of gene in KG-1 and THP-1 cells by downregulating DNMT1 to restore its expression, which results in upregulated expressions of p19, p53 and p21 and induces cell apoptosis.
4.Experience in diagnosis and treatment of infection and bleeding caused by DCD-derived CRKP in kidney transplant recipients
Gang LI ; Chao LI ; Junjie XIE ; Chen YAO ; Zhongwei SUN ; Hongwei BAI ; Yeyong QIAN ; Yanzhong LIU ; Fei YU ; Yuxiang ZHANG ; Jingtao LIU ; Hong LEI ; Lin HE ; Yanfei HAO ; Mengzhu LI ; Yang SONG ; Rong CHEN ; Bingyi SHI
Chinese Journal of Organ Transplantation 2018;39(10):582-585
Objective To investigate the clinical characteristics of DCD donor-derived CRKP infection and bleeding in kidney transplantation,and to summarize the experience of diagnosis,treatment and prevention.Methods A retrospective analysis was carried out from July 2016 to December 2017 in hospital,containing clinical data of 4 cases of CRKP-infected DCD donors and 7 cases of kidney transplantation recipients.Results In the CRKP culture of 4 cases of DCD donors,1 case was positive for blood culture,1 case was positive for urine culture,1 case was positive for sputum culture,and 1 case was negative for blood,urine and sputum culture.The corresponding 7 recipients were all positive for blood culture after renal transplantation,4 cases were positive for urine culture,3 cases were positive for sputum culture,and 5 cases were positive for perirenal drainage.Of the 7 patients,4 cases had renal artery hemorrhage,1 of them was died.The average bleeding time was 17.75 days after operation (14-19 days).In 7 patients with renal transplantation,CRP increasd.And in 3 cases of deaths,CRP was stably higher than normal.Meanwhile,CRP in 4 surviving patients gradually decreased to the normal range after effective anti-infection treatment.All 7 patients were treated with carbapenems;2 patients were dead without avibactam therapy;and 5 cases were treated with avibactam and carbapenems and survived,1 case died and 1 case had good renal function recovery.Conclusion Positive CRKP in blood,urine and sputum of DCD donors can lead to CRKP infection in kidney transplant recipients.Even if the body fluids of donors are all negative,the false negative results could not be excluded.Persistent or increased high-level CRP after operation is an early warning on CRKP infection.And CRP can be used as an indicator for evaluating the effectiveness of anti CRKP therapy.The combination of avibactam and carbapenem antibiotics is an effective regimen in the treatment of DCD donor-derived CRKP.
5.Research progress on application of carbon nanotubes in bone tissue engineering scaffold.
Mengzhu YAO ; Xiaoxia SHENG ; Jun LIN ; Jianqing GAO
Journal of Zhejiang University. Medical sciences 2016;45(2):161-169
Carbon nanotubes possess excellent mechanical and electrical properties and demonstrate broad application prospects in medical fields. Carbon nanotubes are composed of inorganic materials, natural biodegradable polymer or synthetic biodegradable polymer. The composite bone tissue engineering scaffolds are constructed by particle-hole method, lyophilization, microsphere aggregation method, electrostatic spinning or three-dimensional printing. Composite scaffolds overcome the shortcomings of single material and have good biocompatibility, osteoconduction and osteoinduction. With the study of surface chemistry, toxicology, and biocompatibility, a degradable "human-friendly" carbon nanotubes composite bone tissue scaffold will be available; and under the drive of new fabrication techniques, the clinical application of carbon nanotubes composite bone tissue engineering scaffolds will be better developed.
Biocompatible Materials
;
chemistry
;
Bone Development
;
Humans
;
Microspheres
;
Nanotubes, Carbon
;
chemistry
;
Polymers
;
chemistry
;
Printing, Three-Dimensional
;
Tissue Engineering
;
Tissue Scaffolds
;
chemistry
6.New research progress in vitro blood-brain barrier models
Mengzhu LIU ; Yonghua JIN ; Hongmei YU ; Haiqian YAO ; Ying ZHANG ; Shuang ZHANG
Clinical Medicine of China 2016;32(2):189-192
To introduce the biological properties and functions of individual blood-brain barrier components,and summarize the most widely used in vitro blood-brain barrier models,compare their strengths and weaknesses,and provide suggestions on model selection in blood-brain barrier research and new-drug research and development.

Result Analysis
Print
Save
E-mail